Prosecution Insights
Last updated: November 04, 2026

Ernest Pharmaceuticals Inc.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

Ernest Pharmaceuticals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. Keenan Alexander Bates is the busiest examiner, currently managing 1 pending office action. The company's current prosecution is highly focused. With 1 distinct examiner and 1 distinct art unit, the Biotechnology & Pharmaceuticals filings are concentrated under a single review.

Bates is the only examiner with a pending action for this entity. Practitioners can concentrate on the 1 pending office action. Because there is only 1 distinct art unit, the prosecution process is straightforward. The strategy for the portfolio depends on the specific feedback from Keenan Alexander Bates. This centralized environment ensures that prosecution efforts are not diluted across multiple examiners, allowing for a direct and efficient response to the single pending office action within the Biotechnology & Pharmaceuticals technology area.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

0
Hard (0%)
1
Medium (100%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
§103 only1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BATES, KEENAN ALEXANDER 1 44.9% +79.8%

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18276628 INTRACELLULAR DELIVERY OF THERAPEUTIC PROTEINS DESIGNED TO INVADE AND AUTONOMOUSLY LYSE AND METHODS OF USE THEREOF BATES, KEENAN ALEXANDER —

Top Art Units

Art UnitApps
1631 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18276628 INTRACELLULAR DELIVERY OF THERAPEUTIC PROTEINS DESIGNED TO INVADE AND AUTONOMOUSLY LYSE AND METHODS OF USE THEREOF BATES, KEENAN ALEXANDER 1631 §103Other Final Rejection — Pending Aug 09, 2023

Managing Ernest Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Ernest Pharmaceuticals Inc. have?

Ernest Pharmaceuticals Inc. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Ernest Pharmaceuticals Inc. applications?

Keenan Alexander Bates has the most, with 1 of Ernest Pharmaceuticals Inc.'s pending office actions.

What technology area are Ernest Pharmaceuticals Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month